Lytix Biopharma partners on Phase II ALETTA trial of ruxotemitide with ipilimumab, nivolumab in resectable melanoma

• Lytix Biopharma announced an investigator-initiated Phase II melanoma study in Europe testing ruxotemitide with ipilimumab and nivolumab.
• No results have been presented; enrollment for the randomized comparison is expected to start in early 2027.
• Trial targets resectable stage III patients selected for poor response risk to current checkpoint therapy.
• Study aims to determine whether adding ruxotemitide can improve responses before surgery versus standard therapy alone.
• Program expands evidence beyond earlier signals seen with pembrolizumab, supporting broader positioning across leading melanoma regimens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260826:BIT:2693:0) on August 26, 2026, and is solely responsible for the information contained therein.